TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2750681

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation from birth
Number of subjects: 2

Group type: COMPARATOR
Intervention: Unsupplemented
Number of subjects: 2
Study: 208473

Group type: EXPERIMENTAL
Intervention: Orally administered attenuated poliovaccine
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Formalin‐killed poliomyelitis vaccine (inactivated poliovaccine)
Number of subjects: 230

Group type: COMPARATOR
Intervention: No vaccine (control group)
Number of subjects: 230
Study: 31707829

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl 4 g/d
Number of subjects: 3146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3146
Study: 30925147

Group type: EXPERIMENTAL
Intervention: PEEP at 10 cm H₂O (P10)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEEP at 15 cm H₂O (P15)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PEEP at 0 cm H₂O (P0)
Number of subjects: 60
Study: 29390476

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous nephrolithotomy (UGPN)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fluoroscopic-guided percutaneous nephrolithotomy (FGPN)
Number of subjects: 86
Study: 26114843

Group type: EXPERIMENTAL
Intervention: Smartphone ophthalmoscopy (SO) by ophthalmology resident (OR)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Fundus camera (FC) images
Number of subjects: 94
Study: 23904575

Group type: EXPERIMENTAL
Intervention: RBC restoration with RMGI liner
Number of subjects: 341

Group type: COMPARATOR
Intervention: RBC restoration without RMGI liner
Number of subjects: 341
Study: 22313929

Group type: EXPERIMENTAL
Intervention: Filtek Z250 placed incrementally (ZI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Filtek Z250 placed in bulk (ZB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Filtek Silorane placed incrementally (SI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Filtek Silorane placed in bulk (SB)
Number of subjects: 12
Study: 18077214

Group type: EXPERIMENTAL
Intervention: HamSprint programme
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual warm-up (stretching, running, and increasingly intense football drills)
Number of subjects: 29
Study: 18318195

Group type: EXPERIMENTAL
Intervention: Vinpotropil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortexin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noopept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dilept
Number of subjects: 0
Study: 15645323

Group type: EXPERIMENTAL
Intervention: Open appendectomy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Laparoscopic appendectomy
Number of subjects: 37
Study: 12433510

Group type: EXPERIMENTAL
Intervention: Subcutaneous melagatran followed by oral ximelagatran (dose categories: 1.00 mg, 1.50 mg, 2.25 mg, or 3.00 mg twice daily; followed by 8 mg, 12 mg, 18 mg, or 24 mg twice daily)
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Subcutaneous dalteparin 5000 IU once daily
Number of subjects: 1900
Study: 9818340

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide, 500 mg 1 hour preoperatively
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide, 500 mg immediately postoperatively
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride 1%, 2 drops 1 hour preoperatively
Number of subjects: 202

Group type: COMPARATOR
Intervention: Artificial tears (control group)
Number of subjects: 202
Study: 7851351

Group type: EXPERIMENTAL
Intervention: Sufentanil (induction 1.5 micrograms kg‐1 plus infusion 1.5 micrograms kg‐1 h‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fentanyl (induction 10 micrograms kg‐1 plus infusion 10 micrograms kg‐1 h‐1)
Number of subjects: 22
Study: 2553180

Group type: EXPERIMENTAL
Intervention: Late intensification with autologous bone marrow transplantation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional post-induction therapy
Number of subjects: 101
Study: 4164930

Group type: EXPERIMENTAL
Intervention: Indomethacin (doses above 150 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 30
Study: 28950430

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADA + MTX combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low hemoglobin concentrations over time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low hemoglobin concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low disease activity (DAS28-CRP < 3.2)
Number of subjects: 0
Study: 28298244

Group type: EXPERIMENTAL
Intervention: Manual administration of anesthetics guided by BIS sensor
Number of subjects: 430

Group type: COMPARATOR
Intervention: Automated administration of anesthetics
Number of subjects: 430
Study: 25786858

Group type: EXPERIMENTAL
Intervention: Telephone intervention (TI)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Mailed intervention (MI)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 356
Study: 23788583

Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: rtPA+placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: EPO+rtPA
Number of subjects: 90
Study: 20604699

Group type: EXPERIMENTAL
Intervention: Negotiated follow-up with telephone reinforcement (TR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negotiated-only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mainstreamed-with-TR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mainstreamed-only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone reinforcement (TR)
Number of subjects: 0
Study: 18202988

Group type: EXPERIMENTAL
Intervention: Discussion of research, faculty modeling, and role-playing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discussion of research and role-playing
Number of subjects: 0
Study: 15867173

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 2010
Study: 12869078

Group type: EXPERIMENTAL
Intervention: Tioguanine (40 mg tablet preparation)
Number of subjects: 6
Study: 10384971

Group type: EXPERIMENTAL
Intervention: Reliance urinary control insert
Number of subjects: 63
Study: 8678493

Group type: EXPERIMENTAL
Intervention: Endocrine therapies
Number of subjects: 84
Study: 1987962

Group type: EXPERIMENTAL
Intervention: Manual expression with clean containers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Manual expression with sterile containers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mechanical expression with clean containers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mechanical expression with sterile containers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Initial milk expressed
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clean containers
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sterile containers
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual technique
Number of subjects: 16

Group type: COMPARATOR
Intervention: Mechanical technique
Number of subjects: 16
Study: 7033581

Group type: EXPERIMENTAL
Intervention: lodoxamide ethyl
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study: 30444772

Group type: EXPERIMENTAL
Intervention: Endoscopic apicoectomy with endoscopic sinus surgery (ESS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (tooth extraction)
Number of subjects: 21
Study: 29402141

Group type: EXPERIMENTAL
Intervention: Tirasemtiv (125 mg twice a day, escalating to 250, 375, or 500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirasemtiv (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26894313

Group type: EXPERIMENTAL
Intervention: Brief phone-based cognitive-behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no specific intervention mentioned)
Number of subjects: 0
Study: 24535455

Group type: EXPERIMENTAL
Intervention: Rikkunshito (RKT) + rabeprazole (10 mg/day) for 8 weeks
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo + rabeprazole (10 mg/day) for 8 weeks
Number of subjects: 242
Study: 22310081

Group type: EXPERIMENTAL
Intervention: 1.8 mm incision size
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2.2 mm incision size
Number of subjects: 120

Group type: COMPARATOR
Intervention: 3.0 mm incision size
Number of subjects: 120
Study: 19308708

Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention
Number of subjects: 40
Study: 17388233

Group type: EXPERIMENTAL
Intervention: Esmolol 2 mg/kg (E2)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg (E1)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (Eplac)
Number of subjects: 165
Study: 16216469

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (CRO) 100mg/kg once daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) 50 mg/kg 6 hourly
Number of subjects: 33
Study: 11880563

Group type: EXPERIMENTAL
Intervention: lactolycopene
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: tomato paste
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo (whey proteins)
Number of subjects: 33
Study: 10199349

Group type: EXPERIMENTAL
Intervention: Elective caesarean-section delivery
Number of subjects: 436

Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Actual caesarean-section delivery
Number of subjects: 436

Group type: COMPARATOR
Intervention: Actual vaginal delivery
Number of subjects: 436
Study: 7776183

Group type: EXPERIMENTAL
Intervention: Increased exposure to target individual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback about the target's actual thoughts and feelings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-target consistency in responding
Number of subjects: 0
Study: 2108852

Group type: EXPERIMENTAL
Intervention: Aspirin with thrombolytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy alone
Number of subjects: 0
Study: 7353381

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (1,25[OH]2D3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30606246

Group type: EXPERIMENTAL
Intervention: Intramuscular oxytocin
Number of subjects: 5712

Group type: EXPERIMENTAL
Intervention: Intramuscular oxytocin/ergometrine
Number of subjects: 5712

Group type: EXPERIMENTAL
Intervention: Intramuscular carbetocin
Number of subjects: 5712
Study: 29485925

Group type: EXPERIMENTAL
Intervention: Balanced crystalloids (lactated Ringer's solution or Plasma‐Lyte A)
Number of subjects: 15802

Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride)
Number of subjects: 15802

Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 15802

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15802
Study: 26763727

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose (LD)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg LD followed after 2 h by ticagrelor 180 mg re-LD
Number of subjects: 74
Study: 25262934

Group type: EXPERIMENTAL
Intervention: High-oleic canola oil (HOCO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HOCO blended with flaxseed oil (FXCO)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Western diet (WD)
Number of subjects: 36
Study: 22924356

Group type: EXPERIMENTAL
Intervention: Articaine 4% with 1:100 000 adrenaline delivered via Buccal Infiltration (BI)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Lignocaine 2% with 1:80 000 adrenaline delivered via Buccal Infiltration (BI)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Articaine 4% with 1:100 000 adrenaline delivered via Inferior Alveolar Nerve Block (IANB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Lignocaine 2% with 1:80 000 adrenaline delivered via Inferior Alveolar Nerve Block (IANB)
Number of subjects: 57
Study: 19622592

Group type: EXPERIMENTAL
Intervention: Corticosteroid eyedrops (CS), administered six times daily during docetaxel administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Artificial tears (AT), administered six times daily during docetaxel administration
Number of subjects: 20
Study: 18068062

Group type: COMPARATOR
Intervention: Air group (n = 26) - distal cuff inflated with 2 mL of air
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Saline group (n = 26) - distal cuff inflated with 1.2 mL of saline
Number of subjects: 52
Study: 15100507

Group type: EXPERIMENTAL
Intervention: Tl single photon emission computed tomography (SPECT) (38 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: gated 99mTc-MIBI SPECT (42 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Semiquantitative evaluation using SSS and SDS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: gated MIBI study
Number of subjects: 80
Study: 11666119

Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA) 60 mg twice daily for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (similar tablets)
Number of subjects: 0
Study: 9643140

Group type: EXPERIMENTAL
Intervention: Intensive massage
Number of subjects: 30
Study: 8134075

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Control (no aspirin treatment)
Number of subjects: 565
Study: 2570547

Group type: EXPERIMENTAL
Intervention: Metyrosine (alpha‐methylparatyrosine)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 1085738

Group type: EXPERIMENTAL
Intervention: Flufenamic acid ointment (Mobilisin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control preparation
Number of subjects: 100
Study: 31243069

Group type: EXPERIMENTAL
Intervention: Regular nVNS of the left cervical vagal nerve
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham I (stimulation of the posterior neck with the same device)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham II (stimulation of the left cervical vagal nerve with a sham device)
Number of subjects: 28
Study: 28831953

Group type: EXPERIMENTAL
Intervention: TAKE 5 (multi-component weight management programme with energy deficit diet)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waist Winners Too (health education programme)
Number of subjects: 50
Study: 25297466

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI), structured 8-week program of mindfulness training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Psycho-oncological telephone consultation (control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 62
Study: 23498210

Group type: EXPERIMENTAL
Intervention: β-TCP
Number of subjects: 95

Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 95
Study: 21878747

Group type: EXPERIMENTAL
Intervention: Functional electrical therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 20
Study: 19332192

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (specifics not provided)
Number of subjects: 15603
Study: 16505417

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily for 5 years)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: No tamoxifen
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced amenorrhea
Number of subjects: 1246
Study: 15529636

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid 600mg daily IV for 10 days, then 600mg daily for 50 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (29 patients)
Number of subjects: 46
Study: 16940816

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy model of prenatal care, over 20 hours of contact time throughout pregnancy and early postpartum
Number of subjects: 0
Study: 10551494

Group type: EXPERIMENTAL
Intervention: E2F-decoy treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Scrambled-oligodeoxynucleotide treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 41
Study: 8728041

Group type: EXPERIMENTAL
Intervention: Home total parenteral nutrition (TPN; n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dietary counselling (n = 15)
Number of subjects: 31
Study: 1653362

Group type: EXPERIMENTAL
Intervention: CPT-11 at weekly doses of 100 mg/m2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CPT-11 at weekly doses ranging from 50 to 150 mg/m2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CPT-11 at weekly doses
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CPT-11
Number of subjects: 17
Study: 6218370

Group type: EXPERIMENTAL
Intervention: CI2MDP 1600 mg/d
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30846304

Group type: EXPERIMENTAL
Intervention: l-isoproterenol (10 μg/kg/h)
Number of subjects: 83

Group type: COMPARATOR
Intervention: salbutamol (500 μg/kg/h)
Number of subjects: 83
Study: 30193722

Group type: EXPERIMENTAL
Intervention: Gestational weight gain restriction program during pregnancy
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 262
Study: 25421635

Group type: EXPERIMENTAL
Intervention: Movies as a teaching resource
Number of subjects: 0
Study: 24878629

Group type: EXPERIMENTAL
Intervention: Exercising group (DS‐E)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-exercising group (DS‐NE)
Number of subjects: 42
Study: 21773676

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 83
Study: 18990500

Group type: EXPERIMENTAL
Intervention: Brief motivational interventions (BMIs)
Number of subjects: 0
Study: 17908264

Group type: EXPERIMENTAL
Intervention: Combination program
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Alcohol intervention program
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Coping intervention program
Number of subjects: 82
Study: 15724764

Group type: EXPERIMENTAL
Intervention: Participation in a chemoprevention trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased health awareness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personal enhancement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sociability
Number of subjects: 0
Study: 11236045

Group type: EXPERIMENTAL
Intervention: 2 ml sucrose 24% w/v
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: EMLA plus sucrose
Number of subjects: 51

Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 51
Study: 9593779

Group type: EXPERIMENTAL
Intervention: Enteral feeding plus exogenous insulin (200 pmol/h = 28 U/h) with extra glucose as needed (I+G)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous high‐carbohydrate enteral feeding alone (C)
Number of subjects: 6
Study: 8005129

Group type: EXPERIMENTAL
Intervention: 40 mg daily simvastatin
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: 20 mg daily simvastatin
Number of subjects: 621

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 621
Study: 31811485

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - treating team received PAT summary describing low, medium, or high psychosocial risk
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control Group (CG) - no summary provided to treating team
Number of subjects: 183
Study: 30012233

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting list (treatment as usual)
Number of subjects: 50
Study: 26287876

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 200
Study: 23492671

Group type: EXPERIMENTAL
Intervention: BMS and oral prednisone
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 375

Group type: COMPARATOR
Intervention: BMS
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: DES
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Prednisone and DES
Number of subjects: 375
Study: 22151834

Group type: EXPERIMENTAL
Intervention: Smoking cessation counselling [S]
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Smoking cessation + PA counselling [S + PA]
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Control group [C]
Number of subjects: 1100
Study: 19221059

Group type: EXPERIMENTAL
Intervention: 3.0-T MR imaging
Number of subjects: 31
Study: 16546598

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate lotion 0.05% applied once daily for 4 weeks
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo lotion applied once daily for 4 weeks
Number of subjects: 438
Study: 12778391

Group type: EXPERIMENTAL
Intervention: Standard or high-dose cisplatin with etoposide and bleomycin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Delayed surgical resection with organ preservation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cisplatin dose comparison
Number of subjects: 13
Study: 10644301

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0
Study: 9349340

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2, 10 MU/mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tumour necrosis factor alpha (TNF-alpha, 10 micrograms/mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1% histamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Solvent control
Number of subjects: 10
Study: 8103526

Group type: EXPERIMENTAL
Intervention: S-timolol (1 mg, 3 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: R-timolol (25 mg, 75 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: S-timolol (0.5 mg, 1 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: R-timolol (3 mg, 10 mg)
Number of subjects: 11